Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis
Michael Saerens, Nele Brusselaers, Sylvie Rottey, et al.
European Journal of Cancer (2021) Vol. 152, pp. 165-182
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

The roles of tertiary lymphoid structures in chronic diseases
Yuki Sato, Karīna Siliņa, Maries van den Broek, et al.
Nature Reviews Nephrology (2023) Vol. 19, Iss. 8, pp. 525-537
Open Access | Times Cited: 129
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial
Jean‐Yves Blay, Sylvie Chevret, Axel Le Cesne, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 8, pp. 892-902
Closed Access | Times Cited: 43
A Newly Established Cuproptosis-Associated Long Non-Coding RNA Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Soft Tissue Sarcoma
Jun Han, Yunxiang Hu, Sanmao Liu, et al.
Journal of Oncology (2022) Vol. 2022, pp. 1-27
Open Access | Times Cited: 55
Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes
Angiolo Gadducci, Francesco Multinu, Luigi Antonio De Vitis, et al.
Gynecologic Oncology (2023) Vol. 171, pp. 95-105
Closed Access | Times Cited: 28
Immunotherapy in Sarcoma: Current Data and Promising Strategies
Georgina Wood, Christian F. Meyer, Florent Petitprez, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 12
Efficacy of immune checkpoint inhibitors in the treatment of soft tissue sarcoma: A systematic review and meta-analysis of clinical trials
Yang Cao, Wei Wang, Hairong Xu, et al.
International Immunopharmacology (2025) Vol. 148, pp. 114070-114070
Closed Access | Times Cited: 1
Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma
Valentina Evdokimova, Hendrik Gassmann, Laszlo Radvanyi, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 272-272
Open Access | Times Cited: 35
Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells
Peter H. Goff, Laura Riolobos, Bonnie LaFleur, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 8, pp. 1701-1711
Open Access | Times Cited: 30
Targetable Pathways in the Treatment of Retroperitoneal Liposarcoma
Lucia Casadei, Fernanda Costas Casal de Faria, Alexandra G. Lopez‐Aguiar, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1362-1362
Open Access | Times Cited: 23
Tumour-intrinsic endomembrane trafficking by ARF6 shapes an immunosuppressive microenvironment that drives melanomagenesis and response to checkpoint blockade therapy
Yinshen Wee, Junhua Wang, Emily Wilson, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumor-associated macrophages and B-cells
Helena Gustafsson, Mats Jönsson, Mef Nilbert, et al.
Acta Oncologica (2023) Vol. 62, Iss. 1, pp. 33-39
Open Access | Times Cited: 11
Current Landscape of Immunotherapy for Advanced Sarcoma
Víctor Albarrán, María Villamayor, Javier Pozas, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2287-2287
Open Access | Times Cited: 11
Clinical and translational implications of immunotherapy in sarcomas
Federica Recine, Silvia Vanni, Alberto Bongiovanni, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies
Yuzhu Chen, Fei Qi, Chao Sun, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
“From Drowning to Treading Water”: Adolescents and Young Adults Living with Incurable and Indolent Metastatic Soft Tissue Sarcoma for More than Two Years
P D’Alessandro, Caitlin E. Homanick, Brian Y. Cooper, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 442-442
Open Access
Neoadjuvant Treatment Strategies for Patients with Extremity Soft Tissue Sarcomas Across Europe: A Survey from the Young and Early Career Investigator (Y-Eci) Soft Tissue and Bone Sarcoma Group (Stbsg) of the European Organization for Research and Treatment of Cancer (Eortc)
Stijn van der Burg, Melpomeni Kountouri, Jacco J. de Haan, et al.
(2025)
Closed Access
The outcomes and treatment strategies in metastatic soft tissue sarcoma treated with immunotherapy-based therapy: a three-center study
Zhiyong Liu, Weitao Yao, Kang Cui, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Expression of Cancer‐Testis Antigens MAGE‐A1, MAGE‐A4, NY‐ESO‐1 and PRAME in Bone and Soft Tissue Sarcomas: The Experience From a Single Center in China
Anni Chen, Yuling Qiu, Ying‐Tzu Yen, et al.
Cancer Medicine (2025) Vol. 14, Iss. 7
Open Access
Mapping the potential for anti-PD-1 therapy in advanced rare skin carcinomas
Clio Dessinioti, Alexander J. Stratigos
European Journal of Cancer (2025), pp. 115403-115403
Closed Access
The Impact of Resection Margins in Primary Resection of High-Grade Soft Tissue Sarcomas: How Far Is Far Enough?
Julian Miles Steffens, Tymoteusz Budny, Georg Gosheger, et al.
Biomedicines (2025) Vol. 13, Iss. 5, pp. 1011-1011
Open Access
Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention
Marcella Tazzari, Laura Bergamaschi, Alessandro De Vita, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7518-7518
Open Access | Times Cited: 25
Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients
Cheng‐Long Han, Bao‐Wen Tian, Lun‐Jie Yan, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 7, pp. 1957-1969
Open Access | Times Cited: 10
Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy
Maggie Zhou, Nam Q. Bui, Gregory W. Charville, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9571-9571
Open Access | Times Cited: 10
Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study
Zhichao Tian, Shuping Dong, Yang Yang, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 15
Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma
Ying Bi, Zeng‐Hong Wu, Fei Cao
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top